Abbott Labs's most recent trend suggests a bearish bias. One trading opportunity on Abbott Labs is a Bear Call Spread using a strike $117.00 short call and a strike $122.00 long call offers a potential 16.82% return on risk over the next 14 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $117.00 by expiration. The full premium credit of $0.72 would be kept by the premium seller. The risk of $4.28 would be incurred if the stock rose above the $122.00 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Abbott Labs is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Abbott Labs is bearish.
The RSI indicator is at 43.2 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Abbott Labs
Better Dividend King: Johnson & Johnson vs. Abbott Laboratories
Thu, 05 May 2022 11:42:00 +0000
Dividend Kings are stocks that have increased their payouts for 50 years or longer. Although they don't always provide investors with the highest yields, you're likely to see your dividend income rise from holding these types of investments over the years. A couple of Dividend Kings you won't have to worry about paying low payouts today are Johnson & Johnson (NYSE: JNJ) and Abbott Laboratories (NYSE: ABT).
Abbott Obtains FDA Clearance for First Test that Simultaneously Detects Four Common Sexually Transmitted Infections (STIs) as Cases are on the Rise
Wed, 04 May 2022 13:00:00 +0000
Abbott (NYSE: ABT) announced today it has received FDA clearance for its Alinity™ m STI Assay. The test simultaneously detects and differentiates four common sexually transmitted infections (STIs). STIs, when left untreated, can lead to severe health complications, including increased risk of getting certain cancers and infertility.3
The Grandmasters of Virus Surveillance
Mon, 02 May 2022 12:31:07 +0000
Our Pandemic Defense Coalition supports infectious disease research through Virus Hunter mentorships for epidemiologists.
UPDATE 1-Abbott to release some nutrition products halted after baby formula recall
Fri, 29 Apr 2022 21:41:21 +0000
Abbott Laboratories said on Friday it would release limited quantities of nutrition products that had been put on hold following a recall of some powdered infant formulas from its Michigan facility. The company had in February recalled some baby formulas, including certain Similac products, made at its plant in Sturgis after complaints about bacterial infections in infants who consumed the products. That weighed on sales at its nutrition unit in the latest reported quarter and led the company to lower its sales growth view for the full-year.
Abbott to Release Metabolic Nutrition Formulas
Fri, 29 Apr 2022 20:35:00 +0000
At the request of the U.S. Food and Drug Administration (FDA), Abbott (NYSE: ABT) is releasing limited quantities of metabolic nutrition formulas that were previously on hold following Abbott's recall of some powder infant formulas from its Sturgis, Mich., facility. The products have been tested and comply with all product release requirements before distribution. The lots being released were not included in the recall.
Also on Market Tamer…
Follow Us on Facebook